ESMO 2025: Patient Reported Outcomes from AMPLITUDE, a Trial of Niraparib and Abiraterone Acetate plus Prednisone in mHSPC with Homologous Recombination Repair Mutations – UroToday

Written by

admin

in

  1. ESMO 2025: Patient Reported Outcomes from AMPLITUDE, a Trial of Niraparib and Abiraterone Acetate plus Prednisone in mHSPC with Homologous Recombination Repair Mutations  UroToday
  2. Niraparib Combo Boosts rPFS in Metastatic HRR-Altered CSPC  CancerNetwork
  3. JnJ gets USFDA priority review for Akeega plus prednisone for prostate cancer  Medical Dialogues
  4. New Drug Combination May Reduce Risk of Prostate Cancer Progression  Healthgrades Health Library
  5. New drug combination offers hope for men with advanced prostate cancer: Study  Medical Dialogues

Continue Reading

More posts